These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15000578)

  • 1. Use of genotypic assays for the detection of HIV antiretroviral resistance.
    Nicastri E; Ippolito G
    Scand J Infect Dis Suppl; 2003; 106():24-8. PubMed ID: 15000578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The legal proceeding on the use of genotypic assays for the detection of HIV antiretroviral resistance in Italy: background and rationale for a consensus conference to establish guidelines.
    Ippolito G; Visco-Comandini U; Nicastri E
    Scand J Infect Dis Suppl; 2003; 106():8-11. PubMed ID: 15000574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpretation systems for genotypic drug resistance of HIV-1.
    De Luca A; Antinori A; Di Giambenedetto S; Cingolani A; Colafigli M; Perno CF; Cauda R
    Scand J Infect Dis Suppl; 2003; 106():29-34. PubMed ID: 15000579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.
    Visco-Comandini U; Balotta C
    Scand J Infect Dis Suppl; 2003; 106():75-8. PubMed ID: 15000590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supreme Court decision on genotypic tests for antiretroviral drugs resistance: Joint Criminal Divisions.
    Dianzani F; Frascione E
    Scand J Infect Dis Suppl; 2003; 106():108-9. PubMed ID: 15000599
    [No Abstract]   [Full Text] [Related]  

  • 7. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
    Narciso P; Lazzarin A
    Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief summary of the legal proceeding.
    Nicastri E
    Scand J Infect Dis Suppl; 2003; 106():105-7. PubMed ID: 15000598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic resistance testing.
    Andreoni M
    Scand J Infect Dis Suppl; 2003; 106():35-6. PubMed ID: 15000580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpretation of resistance assay results.
    Miller V
    Antivir Ther; 2001; 6 Suppl 2():1-9. PubMed ID: 11678473
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical utility of resistance testing.
    Stebbing J; Gazzard BG
    J HIV Ther; 2002 Nov; 7(4):75-9. PubMed ID: 12733604
    [No Abstract]   [Full Text] [Related]  

  • 12. Rationale and uses of a public HIV drug-resistance database.
    Shafer RW
    J Infect Dis; 2006 Sep; 194 Suppl 1(Suppl 1):S51-8. PubMed ID: 16921473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study.
    Torre D; Tambini R
    HIV Clin Trials; 2002; 3(1):1-8. PubMed ID: 11819179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.
    Montroni M; Monforte AD
    Scand J Infect Dis Suppl; 2003; 106():79-81. PubMed ID: 15000591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.
    Hanna GJ; D'Aquila RT
    Clin Infect Dis; 2001 Mar; 32(5):774-82. PubMed ID: 11229846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting antiretroviral drug resistance from the latest or the cumulative genotype.
    Garcia F; Alvarez M; Fox Z; Garcia-Diaz A; Guillot V; Johnson M; Chueca N; Phillips A; Hernández-Quero J; Geretti AM
    Antivir Ther; 2011; 16(3):373-82. PubMed ID: 21555820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A problem of the HIV drug resistance].
    Nosik MN
    Vopr Virusol; 2014; 59(4):5-9. PubMed ID: 25549461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic resistance tests for the management of the HIV-infected pregnant woman.
    Bassetti D; Cargnel A
    Scand J Infect Dis Suppl; 2003; 106():70-4. PubMed ID: 15000589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.
    Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R;
    Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.